Roth Capital reiterated their buy rating on shares of Heat Biologics Inc. (NASDAQ:HTBX) in a research report released on Thursday morning. Roth Capital currently has a $2.75 price target on the biopharmaceutical company’s stock.
A number of other analysts have also commented on HTBX. Zacks Investment Research lowered Heat Biologics from a buy rating to a hold rating in a research report on Wednesday, July 13th. Noble Financial reissued a buy rating and set a $8.00 price objective on shares of Heat Biologics in a report on Wednesday, August 17th. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and a consensus price target of $6.38.
Shares of Heat Biologics (NASDAQ:HTBX) opened at 1.38 on Thursday. The firm’s market capitalization is $26.90 million. Heat Biologics has a 52-week low of $0.40 and a 52-week high of $5.39. The stock has a 50 day moving average price of $1.46 and a 200-day moving average price of $0.88.
Heat Biologics (NASDAQ:HTBX) last issued its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.10. Equities analysts forecast that Heat Biologics will post ($0.76) EPS for the current year.
A hedge fund recently raised its stake in Heat Biologics stock. Sabby Management LLC raised its stake in shares of Heat Biologics Inc. (NASDAQ:HTBX) by 4,005.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 902,007 shares of the biopharmaceutical company’s stock after buying an additional 880,036 shares during the period. Sabby Management LLC owned approximately 10.71% of Heat Biologics worth $626,000 at the end of the most recent reporting period. 8.63% of the stock is currently owned by institutional investors and hedge funds.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.